“The Alarming Increase of COVID-19 subvariants this Winter.”

What does that mean for our immediate future? New research predicts that four subvariants of the “Omicron” virus that causes COVID-19 will be the most common strains to pass from person to person this winter. The situation is aggravated because the BQ.1, BQ1.1, XBB, and XBB.1 subvariants are highly resistant to the neutralizing antibodies that make up the human immune system. This means that most people have no protection against infection because their immune systems interacting with these four strains are “markedly reduced,” even if people have already had COVID-19 or, indeed, the vaccines worked, and the patient is vaccinated and boosted several times, even with a bivalent vaccine people have no protection. The situation is aggravated because currently available monoclonal antibody treatments are completely ineffective against these subvariants. According to the study “Alarming Antibody-Evasion Properties of Increased SARS-CoV-2 Subvariants BQ and XBB,” published online this week in the journal Cell, currently, the BQ.1 and BQ.1.1 variants account for around 70% of the variants in circulation and are the cause of 18% of hospitalizations in the last 2 weeks. Deaths from COVID-19 also increased by 50% throughout the country, data that has been published by “The New York Times.”

The situation is related to the evolution of the virus towards variants that are successfully replacing BA.5. The latest data from the CDC shows that BA.5 now accounts for only about 10% of the virus in circulation. The researchers estimate that this rapid replacement is increasing the spectrum and risk of another wave of infections in the coming months. Given the weakness of the immune system when facing these strains; the ineffectiveness of monoclonal antibodies; and the ineffectiveness shown by vaccines to protect the organism, even in those cases in which people received all the vaccines and booster doses. It is necessary to find effective therapeutic alternatives that, during the pandemic and after it, have shown relevant results in the prevention, control, treatment and minimization of the transition of infection from severe to critical stages and deaths.

In search for these solutions, we found “DEEP BLOCK”. This product, available on Amazon, has shown from the first cases of infection with the SARS-CoV-2 virus” in 2020 that it is the ideal option for contagion control and stopping the progress of the infection because it has the ability to prevent the entry of viruses and bacteria through the airways (nose, eyes, and mouth); blocking the entry of the virus into cells, thereby preventing replication and infection; and for having anti-inflammatory properties and actions and for modulating the storm of cytokine that, ultimately, is the one that causes the death of patients, so it should be a mandatory product to avoid infections by viruses, bacteria and, in cases like this wave that is coming to us, to control COVID-19.

“DEEP BLOCK” has been on the market for 10 years and, in the control and treatment of COVID-19, has been used successfully since March 2020 by thousands of people in different countries. In Mexico, for example, it was the therapeutic with the highest levels of sales and acceptance for several consecutive months at the peak of the pandemic. The evidence, already published in clinical trials, shows that it is the ideal option for infection control and the evolution of the new wave of COVID-19 In the coming months, in which, up to now, we do not have effective therapeutic products for combat sub-variants BQ.1, BQ1.1, XBB and XBB.1. Using “DEEP BLOCK” at a time when viruses and bacteria circulate will prevent infections, allergies, sore throats, tonsillitis, and hospital admissions, which will contribute to stable work activity and school attendance, thereby increasing the chances of living longer. with quality.